Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (SYRS) reported Q1 2022 revenues of $5.5 million, up from $4.8 million in Q1 2021. The company reported a net loss of $25.1 million or $0.40 per share, compared to a loss of $14.2 million or $0.23 per share in the prior year. Key developments include ongoing trials: SELECT-MDS-1 with expected data in Q4 2023/Q1 2024, and SELECT-AML-1 Phase 2 due in the second half of 2022. The company deprioritized SY-5609 in hematologic malignancies due to current market conditions and plans to secure additional capital before advancing SY-2101 into Phase 3.
Syros Pharmaceuticals (SYRS) announced a live conference call and webcast for May 16, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and provide corporate updates. Investors can access the call via telephone (866-595-4538 domestic) or through the company's website. Syros focuses on developing small molecule medicines that manipulate gene expression and has a pipeline featuring tamibarotene for myelodysplastic syndrome and leukemia, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors and blood cancers.
Syros Pharmaceuticals (NASDAQ: SYRS) has granted 136,750 restricted stock units (RSUs) to six new employees as part of their employment agreement, complying with Nasdaq Listing Rule 5635(c)(4). These awards will vest quarterly, starting April 30, 2023, contingent on continued employment. Syros is focused on developing innovative gene expression medicines, with a pipeline that includes tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors and blood cancers.
Syros Pharmaceuticals (SYRS) announced promising preclinical results for its CDK12 inhibitor program, showcasing strong anti-tumor activity in breast, lung, and ovarian cancer models. The data, presented at the AACR Annual Meeting 2022, indicate that the CDK12 inhibitors have low nanomolar potency and selectivity against other CDKs. The inhibitors demonstrated significant tumor regression in animal models and synergy with DNA damaging agents. Syros plans to nominate a development candidate in the second half of 2022, targeting patients resistant to current therapies.
Syros Pharmaceuticals (NASDAQ: SYRS) announced the grant of restricted stock unit (RSU) awards totaling 89,400 shares to three new employees as inducements for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with one-quarter of the shares vesting on each anniversary of the grant date, contingent on continued service. This strategic move aims to attract talent as the company advances its clinical-stage pipeline targeting gene expression control in various cancers.
Syros Pharmaceuticals (SYRS) reported Q4 and full-year 2021 financial results, highlighting a net loss of $23.8 million for Q4 and $86.6 million for the year. Total revenues were $7.8 million in Q4 and $23.5 million for 2021, up from $5.7 million and $15.1 million respectively in 2020. Key upcoming milestones include reporting pharmacokinetic and safety data for SY-2101 and clinical activity from SY-5609 in pancreatic cancer in mid-2022. Syros maintains $143.4 million in cash, expected to cover operations into Q1 2023.
Syros Pharmaceuticals (NASDAQ:SYRS) is set to host a live conference call and webcast on March 15, 2022, at 8:30 a.m. ET, to discuss its fourth quarter and full year 2021 financial results. The call can be accessed via phone at (866) 595-4538 for domestic calls and (636) 812-6496 internationally, using conference ID 9682507. Syros is advancing a clinical-stage pipeline with key products like tamibarotene and SY-2101 targeting myeloid malignancies and acute promyelocytic leukemia, respectively. A webcast will be available for 30 days post-event on Syros’ website.
Syros Pharmaceuticals (NASDAQ:SYRS) announced the presentation of new preclinical data on its CDK12 inhibitor program at the AACR Annual Meeting 2022, scheduled from April 8-13 in New Orleans, Louisiana. The e-poster will reveal that the selective CDK12 inhibitor exhibits strong anti-tumor activity both in vitro and in vivo across various cancer models and shows improved effects when combined with DNA-damaging agents. Syros aims to nominate a development candidate from this program in the latter half of 2022.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in two virtual investor conferences in March. She will present at the Cowen 42nd Annual Healthcare Conference on March 7 at 12:50 p.m. ET and at the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 3:20 p.m. ET. Management will also hold one-on-one meetings. Archived recordings will be available on Syros' website.
Syros focuses on developing gene expression medicines with a diverse clinical pipeline, including treatments for myelodysplastic syndrome, acute myeloid leukemia, and solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) has announced that the U.S. FDA granted orphan drug designation to tamibarotene for treating myelodysplastic syndrome (MDS). Tamibarotene, a selective retinoic acid receptor alpha agonist, is being evaluated in the SELECT-MDS-1 Phase 3 trial alongside azacitidine for RARA-positive HR-MDS patients. The drug's designation may offer benefits including market exclusivity and tax credits. Data from the trial is expected in late 2023 or early 2024, with potential new drug application filing anticipated in 2024.
FAQ
What is the current stock price of Syros Pharmaceuticals (SYRS)?
What is the market cap of Syros Pharmaceuticals (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
